ClinicalTrials.Veeva
Menu

Find clinical trials for Colon Cancer in Philadelphia, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Colonic Cancer
Cancer
Neoplasm Metastasis
Adenocarcinoma
Lung Cancer
Non-Small-Cell Lung Carcinoma

Colon Cancer trials near Philadelphia, PA, USA:

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (AZUR-2)

(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...

Enrolling
Colonic Neoplasms
Neoplasms, Colon
Drug: FOLFOX
Biological: Dostarlimab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Wynnewood, Pennsylvania, United States and 212 other locations

The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in mea ...

Active, not recruiting
Microsatellite Unstable Colorectal Cancer
Microsatellite Stable Colorectal Cancer
Drug: Ipilimumab
Drug: Daratumumab

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Allentown, Pennsylvania, United States and 32 other locations

doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZ...

Active, not recruiting
Breast Cancer
Colon Neoplasms
Drug: AZD6244
Drug: Erlotinib

Phase 1

AstraZeneca
AstraZeneca

Philadelphia, Pennsylvania, United States and 3 other locations

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing...

Enrolling
Colon Cancer
Lung Cancer
Drug: RSC-1255 Dose Expansion
Drug: RSC-1255 Dose Escalation

Phase 1

Rascal Therapeutics

Philadelphia, Pennsylvania, United States and 5 other locations

to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer...

Enrolling
Colon Cancer
Medullary Thyroid Cancer
Drug: LOXO-292

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

Philadelphia, Pennsylvania, United States and 83 other locations

the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon...

Enrolling
Stage III Colon Cancer
Drug: mFOLFOX6 3-6 month
Device: Signatera test

Phase 2, Phase 3

NRG Oncology

Philadelphia, Pennsylvania, United States and 831 other locations

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...

Enrolling
Malignant Pleural Mesothelioma
Colorectal Adenocarcinoma
Drug: 5-fluorouracil
Drug: Irinotecan

Phase 1

Inhibrx

Philadelphia, Pennsylvania, United States and 18 other locations

This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET...

Enrolling
Papillary Thyroid Cancer
Medullary Thyroid Cancer
Drug: LOXO-292

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

Philadelphia, Pennsylvania, United States and 25 other locations

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with adva...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: MRTX849
Drug: Afatinib

Phase 1, Phase 2

Mirati Therapeutics
Mirati Therapeutics

Media, Pennsylvania, United States and 97 other locations

with either (a) hepatocellular carcinoma (HCC) that is not amenable to resection, transplant or other potentially curative therapy or (b) cancer...

Active, not recruiting
Metastatic Colorectal Cancer
Metastatic Pancreatic Cancer
Drug: PV-10 (10% rose bengal disodium)

Phase 1

Provectus Biopharmaceuticals

Bethlehem, Pennsylvania, United States and 4 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems